When expressing protein, there are a variety of expression systems to choose from. CHO is seen as the ‘king’ in the industry, but does it meet all needs of rapid production and budget constraints? This meeting will explore “Optimizing Protein Expression” through understanding and enhancing expression systems, and will especially focus on CHO cells, and other mammalian systems, E.coli and yeasts. Other host systems, such as baculovirus and algae, will be touched on as well.

Along with case studies, the meeting will feature experts who reveal the underlying mechanisms and insights into the varying systems in order to enhance protein expression. Comparing and contrasting systems will also be featured to provide greater understanding of how these systems function within the context of the results achieved.

Learn the latest protocols and see how protein science leaders are enhancing expression systems to reach greater productivity.


Expression and Purification of Proteins for Drug Discovery – Challenges and Trends

Ian Hunt, Ph.D., Group Leader, Protein Sciences, Center for Proteomic Chemistry, Novartis, NIBR

Multiple Approaches to Optimize Protein Production for Shortening the Discovery Process of Non-Antibody Protein Therapeutics

Liang Tang, Ph.D., Principal Research Scientist II, Bayer HealthCare

Reducing Manufacturing Costs from the Start: Optimization of COGs at the Early Cell Line Development Stage

Irene Liu, Ph.D., Associate Scientist, Cell Line Development, Pre-Pivotal Drug Substance-PD, Amgen, Inc.


Enhanced Synthesis of Recombinant Phosphoproteins in E. coli is Enabled by a New Genetic Code

Jesse Rinehart, Ph.D., Assistant Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine

An Overview and History of Glyco-Engineering in Insect Expression Systems

Donald L. Jarvis, Ph.D., Professor, Molecular Biology, University of Wyoming

Antigen Generation for Antibody Lead Discovery – Modular Expression Approaches using Transient and Stable Mammalian Production

Mark Trautwein, Ph.D., Senior Research Scientist, Global Biologics, Bayer HealthCare Pharma


A Direct qPCR Method for Residual DNA Quantification in Monoclonal Antibody Drugs Produced in CHO Cells

Musaddeq Hussain, Ph.D., Principal Scientist, BioProcess Development, Biologics and Vaccines Research, Merck Research Laboratories

Engineered CHO Cells for Production of Diverse, Homogeneous Glycoproteins

Malene Bech Vester-Christensen, Ph.D., Team Leader, Recombinant Expression Technologies, Novo Nordisk A/S

To Fucosylate or Not: Utilizing FX Knockout CHO Lines to Express WT or Afycosylated Antibodies on Command

Shahram Misaghi, Ph.D., Scientist, Early Stage Cell Culture, Genentech, a member of the Roche Group

miRNA Engineering of CHO Cells

Vaibhav Jadhav, Ph.D., Scientist, Austrian Centre of Industrial Biotechnology, ACIB

Expression of the Human Cytomegalovirus Pentamer Complex for Vaccine Use in a CHO System

Andrea Carfi, Ph.D., U.S. Head, Protein Biochemistry, Novartis Vaccines and Diagnostics


Genomically Encoded Analog Memory with Precise In Vivo DNA Writing in Living Cell Populations

Timothy K. Lu, Ph.D., Assistant Professor, Biological & Electrical Engineering, Massachusetts Institute of Technology (MIT)

Identification of Novel Regulators of Recombinant Protein Expression using Phenotypic Screening Followed by Target Validation using CRISPR/Cas9

Robert Roth, Ph.D., Associate Principle Scientist, Reagents and Assay Development, Discovery Sciences iMed, AstraZeneca

For more details on the conference,
please contact:

For partnering and sponsorship information, please contact:

Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
T: 781-972-5421

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471